New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder

J&J’s Caplyta doubles remission rate in MDD patients

J&J presented the new analysis from three Phase III trials of Caplyta in MDD.The post J&J’s Caplyta doubles remission rate in MDD patients appeared first on Clinical Trials Arena.

New Phase 3 Data Analysis: Lumateperone Shows Promise for Remission of Major Depressive Disorder

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder

CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data from two Phase 3 studies 65% of patients reached remission with CAPLYTA®, with 43% achieving sustained relief from symptoms, in a six-month open-label extension safety study Newly approved as an adjunctive for major depressive disorder, CAPLYTA® supports the ultimate treatment goal of remission w…